Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model

Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model

Multiple myeloma (MM) is a hematological disease characterized by the proliferation and accumulation of malignant plasmacells (PCs) in the bone marrow (BM). Despite widespread use of high-dose chemotherapy in combination with autologous stem cell transplantation (ASCT) and the introduction of novel...

Full description

Bibliographic Details
Main Authors:	Beatrice Anna Zannetti, Angelo Corso Faini, Evita Massari, Massimo Geuna, Enrico Maffini, Giovanni Poletti, Claudio Cerchione, Giovanni Martinelli, Fabio Malavasi, Francesco Lanza
Format:	Article
Language:	English
Published:	MDPI AG 2020-12-01
Series:	Cells
Subjects:	CD38 plasmacells multiple myeloma CD38 antigen expression in various tissues bone marrow microenvironment anti-CD38 monoclonal antibodies
Online Access:	https://www.mdpi.com/2073-4409/9/12/2666

Similar Items

The Circular Life of Human CD38: From Basic Science to Clinics and Back
by: Alberto L. Horenstein, et al.
Published: (2020-10-01)

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
by: Torben Plesner, et al.
Published: (2020-02-01)

NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias
by: Renato Zambello, et al.
Published: (2020-03-01)

Removal of serological interference in the treatment of multiple myeloma with CD38 monoclonal antibody using polybrene method
by: Yan ZHENG, et al.
Published: (2022-08-01)

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
by: Fabio Morandi, et al.
Published: (2018-11-01)

Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects
by: Alberto L. Horenstein, et al.
Published: (2025-02-01)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
by: Ilaria Saltarella, et al.
Published: (2020-01-01)

The roles of CD38 and CD157 in the solid tumor microenvironment and cancer immunotherapy
by: Wo, Yu Jun, et al.
Published: (2020)

Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38
by: Song Li, et al.
Published: (2024-06-01)

Anti CD38 monoclonal antibodies for multiple myeloma treatment
by: Alessandro Gozzetti, et al.
Published: (2022-11-01)

Roles of CD38 in the Immune Response to Infection
by: Estibaliz Glaría, et al.
Published: (2020-01-01)

CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy
by: Alberto L. Horenstein, et al.
Published: (2019-04-01)

A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma
by: Hongwen Li, et al.
Published: (2023-05-01)

Evaluation of CD38 expression in Sudanese patients with chronic lymphocytic leukemia
by: Enaam Abdelrhman Abdelgader, et al.
Published: (2018-11-01)

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
by: Kamlesh Bisht, et al.
Published: (2023-10-01)

Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma
by: Peter Bannas, et al.
Published: (2018-11-01)

Prospective two center study of CD38 bright CD8+ effector memory T-cells as a predictor of acute GVHD
by: Pooja Khandelwal, et al.
Published: (2022-09-01)

Targeting CD38 for acute leukemia
by: Xushu Zhong, et al.
Published: (2022-10-01)

An approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/lambda ratios of CD38-gated CD138<sup>+</sup> cells
by: Nakayama Shoko, et al.
Published: (2012-09-01)

Using cluster of differentiation CD 38, CD 45 and CD 95 as a method of primary diagnosis of uterine fibroids
by: I. V. Savytskyi, et al.
Published: (2017-07-01)

Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors
by: Alberto L. Horenstein, et al.
Published: (2018-04-01)

Expression of CD38 in Mast Cells: Cytological and Histotopographic Features
by: Dmitri Atiakshin, et al.
Published: (2021-09-01)

CD38 Drives Progress of Osteoarthritis by Affecting Cartilage Homeostasis
by: Jin‐jin Ma, et al.
Published: (2022-05-01)

Harnessing the Power of CAR-NK Cells: A Promising Off-the-Shelf Therapeutic Strategy for CD38-Positive Malignancies
by: Maryam Asadi, et al.
Published: (2023-12-01)

INTEREST IN DETERMINING THE CD34+ CD38- PHENOTYPE IN THE DIAGNOSIS AND PROGNOSIS OF ACUTE LEUKEMIA IN ABIDJAN – CÔTE D’IVOIRE
by: Duni Sawadogo, et al.
Published: (2013-04-01)

CD4+CD38+ central memory T cells contribute to HIV persistence in HIV-infected individuals on long-term ART
by: Cheng-Bo Song, et al.
Published: (2020-02-01)

Evaluation of diagnostic potential of CD38 in rickets
by: Yongjie Xia, et al.
Published: (2024-02-01)

Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity
by: Wei Liu, et al.
Published: (2024-05-01)

FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma
by: Guangbing Zhang, et al.
Published: (2022-12-01)

Editorial: Immunotherapy in Multiple Myeloma
by: Nicola Giuliani, et al.
Published: (2019-08-01)

CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy
by: Luca Julius Pape, et al.
Published: (2022-10-01)

CD38+CD39+ NK cells associate with HIV disease progression and negatively regulate T cell proliferation
by: Shi Qian, et al.
Published: (2022-10-01)

CD38‐NADase is a new major contributor to Duchenne muscular dystrophic phenotype
by: Antoine de Zélicourt, et al.
Published: (2022-03-01)

The CD39/CD73/Adenosine and NAD/CD38/CD203a/CD73 Axis in Cutaneous T-Cell Lymphomas
by: Liyun Lin, et al.
Published: (2025-02-01)

Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma
by: Xiaorui Li, et al.
Published: (2021-08-01)

Evaluation of Mycobacterium tuberculosis specific antigen-stimulated CD27−CD38+IFN-γ+CD4+ T cells for discrimination of active tuberculosis
by: Yong Fang, et al.
Published: (2022-12-01)

The role of CD38 in HIV infection
by: Liqi Lu, et al.
Published: (2021-04-01)

Design, Synthesis and SAR Studies of NAD Analogues as Potent Inhibitors towards CD38 NADase
by: Shengjun Wang, et al.
Published: (2014-09-01)

End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy
by: Pierre Sesques, et al.
Published: (2024-10-01)

CD38 regulates chronic lymphocytic leukemia proliferation via CD45 phosphatase activity
by: John F. Imbery, et al.
Published: (2024-09-01)